Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, Spitznagel EL, Piccirillo J. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24(28):4539–44.

Article  PubMed  Google Scholar 

Bradley JD, Hu C, Komaki RR, Masters GA, Blumenschein GR, Schild SE, Bogart JA, Forster KM, Magliocco AM, Kavadi VS, et al. Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2020;38(7):706–14.

Article  CAS  PubMed  Google Scholar 

Ishida K, Hirose T, Yokouchi J, Oki Y, Kusumoto S, Sugiyama T, Ishida H, Shirai T, Nakashima M, Yamaoka T, et al. Phase II study of concurrent chemoradiotherapy with carboplatin and vinorelbine for locally advanced non-small-cell lung cancer. Mol Clin Oncol. 2014;2(3):405–10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16(2):187–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, Vansteenkiste JF, Garassino MC, Hui R, Quantin X, et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022;40(12):1301–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;379(24):2342–50.

Article  CAS  PubMed  Google Scholar 

Troncone M, Cargnelli SM, Villani LA, Isfahanian N, Broadfield LA, Zychla L, Wright J, Pond G, Steinberg GR, Tsakiridis T. Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy: translational biology and rationale for current clinical trials. Oncotarget. 2017;8(34):57733–54.

Article  PubMed  PubMed Central  Google Scholar 

Storozhuk Y, Hopmans SN, Sanli T, Barron C, Tsiani E, Cutz JC, Pond G, Wright J, Singh G, Tsakiridis T. Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. Br J Cancer. 2013;108(10):2021–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsakiridis T, Pond GR, Wright J, Ellis PM, Ahmed N, Abdulkarim B, Roa W, Robinson A, Swaminath A, Okawara G, et al. Metformin in Combination With Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer: The OCOG-ALMERA Randomized Clinical Trial. JAMA Oncol. 2021;7(9):1333–41.

Article  PubMed  PubMed Central  Google Scholar 

Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, Zhang HP, Donnellan M, Mahler S, Pryor K, et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A. 1997;94(21):11514–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Strelau J, Bottner M, Lingor P, Suter-Crazzolara C, Galter D, Jaszai J, Sullivan A, Schober A, Krieglstein K, Unsicker K. GDF-15/MIC-1 a novel member of the TGF-beta superfamily. J Neural Transm Suppl. 2000;60:273–6.

Google Scholar 

Wang D, Day EA, Townsend LK, Djordjevic D, Jorgensen SB, Steinberg GR. GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease. Nat Rev Endocrinol. 2021;17(10):592–607.

Article  CAS  PubMed  Google Scholar 

Brown DA, Bauskin AR, Fairlie WD, Smith MD, Liu T, Xu N, Breit SN. Antibody-based approach to high-volume genotyping for MIC-1 polymorphism. Biotechniques. 2002;33(1):118–20. 122, 124 passim.

Article  CAS  PubMed  Google Scholar 

Brown DA, Ward RL, Buckhaults P, Liu T, Romans KE, Hawkins NJ, Bauskin AR, Kinzler KW, Vogelstein B, Breit SN. MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res. 2003;9(7):2642–50.

CAS  PubMed  Google Scholar 

Tsai VWW, Husaini Y, Sainsbury A, Brown DA, Breit SN. The MIC-1/GDF15-GFRAL Pathway in Energy Homeostasis: Implications for Obesity, Cachexia, and Other Associated Diseases. Cell Metab. 2018;28(3):353–68.

Article  CAS  PubMed  Google Scholar 

Mullican SE, Lin-Schmidt X, Chin CN, Chavez JA, Furman JL, Armstrong AA, Beck SC, South VJ, Dinh TQ, Cash-Mason TD, et al. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. Nat Med. 2017;23(10):1150–7.

Article  CAS  PubMed  Google Scholar 

Wang D, Townsend LK, DesOrmeaux GJ, Frangos SM, Batchuluun B, Dumont L, Kuhre RE, Ahmadi E, Hu S, Rebalka IA, et al. GDF15 promotes weight loss by enhancing energy expenditure in muscle. Nature. 2023;619(7968):143–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Breen DM, Kim H, Bennett D, Calle RA, Collins S, Esquejo RM, He T, Joaquim S, Joyce A, Lambert M, et al. GDF-15 Neutralization Alleviates Platinum-Based Chemotherapy-Induced Emesis, Anorexia, and Weight Loss in Mice and Nonhuman Primates. Cell Metab. 2020;32(6):938–e950936.

Article  CAS  PubMed  Google Scholar 

Sandor N, Schilling-Toth B, Kis E, Benedek A, Lumniczky K, Safrany G, Hegyesi H. Growth Differentiation Factor-15 (GDF-15) is a potential marker of radiation response and radiation sensitivity. Mutat Res Genet Toxicol Environ Mutagen. 2015;793:142–9.

Article  CAS  PubMed  Google Scholar 

Gerstein HC, Pare G, Hess S, Ford RJ, Sjaarda J, Raman K, McQueen M, Lee S, Haenel H, Steinberg GR, et al. Growth Differentiation Factor 15 as a Novel Biomarker for Metformin. Diabetes Care. 2017;40(2):280–3.

Article  CAS  PubMed  Google Scholar 

Day EA, Ford RJ, Smith BK, Mohammadi-Shemirani P, Morrow MR, Gutgesell RM, Lu R, Raphenya AR, Kabiri M, McArthur AG, et al. Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss. Nat Metab. 2019;1(12):1202–8.

Article  CAS  PubMed  Google Scholar 

Ali A, Mekhaeil B, Biziotis OD, Tsakiridis EE, Ahmadi E, Wu J, Wang S, Singh K, Menjolian G, Farrell T, et al. The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy. Commun Biol. 2023;6(1):919.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li S, Lu X, Feng JB, Tian M, Wang J, Chen H, Chen DQ, Liu QJ. Developing Gender-Specific Gene Expression Biodosimetry Using a Panel of Radiation-Responsive Genes for Determining Radiation Dose in Human Peripheral Blood. Radiat Res. 2019;192(4):399–409.

Article  CAS  PubMed  Google Scholar 

Wischhusen J, Melero I, Fridman WH. Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint. Front Immunol. 2020;11:951.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Deng J, Zhang M, Zhang H, Lu C, Hou G, Feng Y, Fang Z, Lv X. Value of Growth/Differentiation Factor 15 in Diagnosis and the Evaluation of Chemotherapeutic Response in Lung Cancer. Clin Ther. 2021;43(4):747–59.

Article  CAS  PubMed  Google Scholar 

Landberg T, Chavaudra J, Dobbs J, Gerard J-P, Hanks G, Horiot J-C, Johansson K-A, Möller T, Purdy J, Suntharalingam N et al. Report 62. Journal of the International Commission on Radiation Units and Measurements 2016, os32(1).

Liu YN, Wang XB, Wang T, Zhang C, Zhang KP, Zhi XY, Zhang W, Sun KL. Macrophage Inhibitory Cytokine-1 as a Novel Diagnostic and Prognostic Biomarker in Stage I and II Nonsmall Cell Lung Cancer. Chin Med J (Engl). 2016;129(17):2026–32.

Article  CAS  PubMed  Google Scholar 

Xu C, Li L, Wang W, Zhang Q, Zhang X, Yang R. Serum macrophage inhibitory cytokine-1 as a clinical marker for non-small cell lung cancer. J Cell Mol Med. 2021;25(6):3169–72.

Article  CAS  PubMed  PubMed Central  Google Scholar